COVID-19 VACCINATIONS: If, in addition to indemnity for your main employment, you would like cover for delivering COVID-19 Vaccinations please apply for our standalone extension Apply Today

Home  »   National Association of Women PharmacistsLatest News   »   NAWP welcomes Boots’ announcement that it will pay for team members’ HRT prescriptions

NAWP welcomes Boots’ announcement that it will pay for team members’ HRT prescriptions

The National Association of Women Pharmacists (NAWP) has welcomed an announcement of additional support from Boots for employees requiring Hormone Replacement Treatment (HRT).

Wed 23rd March 2022 The PDA

Pharmacists should be aware that it is not just their patients who experience menopause, it is an issue in the workplace too. As around 50% of the world’s population consists of women, even if some will not experience menopause themselves, there will be female colleagues who will do so at some point in their lives.

NAWP has long been raising the profile of women’s health issues for working pharmacists and has published several factsheets to assist employed and locum pharmacists as well as their employers. This includes a menopause factsheet that can be found here.

NAWP, therefore, welcomes the news that the largest employer of pharmacists in the UK, Boots, has announced that it will provide additional support for pharmacists and other team members who need Hormone Replacement Treatment (HRT). Boots is supporting team members experiencing menopausal symptoms by removing the barrier of prescription costs, an initiative that could help them save individuals up to £224 per year.

Around 80% of Boots’ 51,000 employees are women and around 8,600 Boots team members are currently in scope to access HRT which helps relieve the symptoms of menopause. From April 2022, Boots will cover the cost of its team members’ prescriptions for those able and wanting to take HRT.

Prescriptions are free of charge in Wales, Scotland, and Northern Ireland, but most Boots team members are faced with a prescription charge from NHS England, so this will be an added benefit of working at Boots.

Daniela Rusalim, Vice-President of NAWP and a pharmacist employed at Boots said, “This is a very welcome announcement of additional support from Boots for a health issue that impacts women at work. NAWP and the wider PDA are always pleased to give credit where it is due and welcome this initiative. We also welcome Boots stated aim to become a menopause-friendly employer. 

The pharmacist profession is two-thirds female and NAWP would like to see other employers in the UK introduce similar support for their employees.”

Related links

Get Involved

  • Follow the PDA NAWP Network on social media using the hashtag #PDAnawp
  • For more information about the PDA NAWP Network, click here.
  • If you would like to get involved with the network and its activities, please email: nawp@the-pda.org

JOIN THE PDA NAWP NETWORK TODAY

Not yet a PDA member?

If you have not yet joined the PDA, we encourage you to join today and ask your colleagues to do the same.

Membership is FREE to pharmacy students, trainee pharmacists and for the first three months of being newly qualified.

JOIN THE PDA TODAY

Read about our key member benefits here.

 

 

 

 

 

The Pharmacists' Defence Association is a company limited by guarantee. Registered in England; Company No 4746656.

The Pharmacists' Defence Association is an appointed representative in respect of insurance mediation activities only of
The Pharmacy Insurance Agency Limited which is registered in England and Wales under company number 2591975
and is authorised and regulated by the Financial Conduct Authority (Register No 307063)

The PDA Union is recognised by the Certification Officer as an independent trade union.

Cookie Use

This website uses cookies to help us provide the best user experience. If you continue browsing you are giving your consent to our use of cookies.

General Guidance Resources Surveys PDA Campaigns Regulations Locums Indemnity Arrangements Pre-Regs & Students FAQs Coronavirus (COVID-19)